8.84
+0.34(+4.00%)
Currency In USD
| Previous Close | 8.5 |
| Open | 8.56 |
| Day High | 8.95 |
| Day Low | 8.43 |
| 52-Week High | 8.96 |
| 52-Week Low | 2.32 |
| Volume | 605,611 |
| Average Volume | 664,371 |
| Market Cap | 478.17M |
| PE | -7.49 |
| EPS | -1.18 |
| Moving Average 50 Days | 7.09 |
| Moving Average 200 Days | 5.34 |
| Change | 0.34 |
If you invested $1000 in Fulcrum Therapeutics, Inc. (FULC) since IPO date, it would be worth $654.81 as of September 29, 2025 at a share price of $8.84. Whereas If you bought $1000 worth of Fulcrum Therapeutics, Inc. (FULC) shares 5 years ago, it would be worth $1,158.58 as of September 29, 2025 at a share price of $8.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
GlobeNewswire Inc.
Aug 26, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defin
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
GlobeNewswire Inc.
Jul 29, 2025 10:45 AM GMT
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
GlobeNewswire Inc.
Jul 28, 2025 8:01 PM GMT
CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rar